Please login to the form below

Not currently logged in
Email:
Password:

Pharma news in brief

Our weekly round-up of news affecting the industry

Celgene defends Revlimid price

Celgene has defended the price of its new medicine for a rare blood disease, Revlimid, saying it will save the US healthcare system money.

Chief executive John Jackson (who will step down in May but continue as chairman) said the company would charge between $4,500 and $4,700 a month for Revlimid, which comes to between $54,000 and $56,400 annually. He added that patients with the disease, myelodysplastic syndrome, currently require frequent blood transfusions, which are even more expensive.

The US Food and Drug Administration approved the drug last week for a subset of patients with the blood disease.

GSK lobbying for rule change

GSK has called for authorities such as the US Federal Trade Commission to waive their usual rules to allow vaccine manufacturers to work together to help the fight against a future flu pandemic.

Speaking to the Financial Times, GSK chief executive Jean-Pierre Garnier said his company would like to co-operate with other vaccine manufacturers ìbut the US needs to clear that with the FTC and the Food and Drug Administration.î

He said such a move, which would currently breach antitrust rules, could allow quicker and more efficient production of important vaccines.

Busy month for British biotech

A busy month for British biotech deals has been rounded off by AstraZeneca's purchase of cancer-focused KuDOS Pharmaceuticals, a privately held company in Cambridge, for $210m (£121m).

Prior to this, Spanish firm Alimirall agreed to pay GW Pharmaceuticals up to £43m to secure the rights to market its cannabis-based treatment for multiple sclerosis, Sativex, in Europe, excluding the UK.

Earlier in December, Astex, another privately owned biotech firm, landed a deal worth up to $520m when Novartis moved for its promising cancer treatment.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics